ALZN Company Profile and Key Details

Alzamend Neuro, Inc. (NASDAQ:ALZN) closed at $1.08 USD, losing -$0.03 (-2.70%) from the previous close of $1.11. The stock is currently mid-range between its 52-week high and low $0.84 and $8.22. With a market capitalization of about $3.39 million, Alzamend Neuro, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.05). Key stats such as the average daily volume over the past year has been around 140.54 thousand shares, volume is running light vs its 52-week average. Headquartered in Atlanta, GA, Alzamend Neuro, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephan Jackman, the company employs approximately 4 people and listed since June 15, 2021. Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

ALZN has shown sold momentum, gaining 3.86% over the past week and 9.01% over the past quarter, though year-to-date performance is up 32.97%. Short-term trend indicators are bullishly aligned (SMA20 6.39%, SMA50 -0.25%, SMA200 -18.35%). The stock’s 14-day RSI is 53.33 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.55% below its high and over 31.65% above its low. Average 10-day trading volume of 62.92 thousand shares is below the 3-month average of 105.25 thousand, indicating normal recent market interest.

Alzamend Neuro, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.02. This means the shares are trading above this model’s fair value.

Alzamend Neuro, Inc. generated EPS of -$5.50 over the past year. Five-year average earnings growth is 30.49%. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.53. Next year's EPS is expected at -$17.63. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $42.00. The high target offers 4066.67% upside. The low target suggests 3788.89% downside. The mean target is $43.00. This offers 3881.48% upside. Alzamend Neuro, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended December 09, 2025, missed forecasts by -63.86%. The prior quarter beat by -65.31%. Over the last six quarters, Apple has recorded several small beats. These include -47.48% in September 11, 2024.

Alzamend Neuro, Inc. has 3.80 million shares outstanding. The public float is 3.79 million shares, elevated short interest at 8.62% of float. This equals 326.19 thousand shares. The short ratio is 1.33 days. Institutional investors hold 3.97% of the float. Insiders own 2.26%. AULT MILTON C III holds 116.65 thousand shares, GUSTAFSON MARK has 60.00 thousand shares and Jackman Stephan has 45.50 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.18 thousand shares across 2 transactions.